Loading...
OTCM
VDRM
Market cap2mUSD
Aug 01, Last price  
0.00USD
1D
183.33%
1Q
-83.50%
Jan 2017
-32.00%
IPO
-99.99%
Name

Viaderma Inc

Chart & Performance

D1W1MN
No data to show
P/E
511.91
P/S
3.49
EPS
0.00
Div Yield, %
Shrs. gr., 5y
22.58%
Rev. gr., 5y
67.19%
Revenues
600k
+11.07%
17,95815,90425,262,56226,828,83319,007,639191,777251,98144,69145,97310,39511,468514,007540,648600,498
Net income
4k
-99.31%
-141,484-19,0844,094,6234,506,9262,672,78527,121-121,806-1,518,384-2,998,022-599,270-431,673-994,178590,6744,097
CFO
0k
-21,6641,6913,308,0437,777,0546,054,149-11,189-12,064-167,361-83,901-15,116-8,769000
Earnings
Oct 01, 2025

Profile

ViaDerma, Inc. operates as a specialty pharmaceutical company in the United States. It focuses on developing and marketing pharmaceutical products, as well as licensing its technology to companies in the pharmaceutical industry in various therapeutic areas. The company's lead product is Vitastem, a tetracycline-based topical antibiotic used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. It is also developing products in various fields of use, including topical antibiotics, toenail antifungal drugs, diabetic amputations, global acne, psoriasis, and eczema, as well as burns, anti-aging/wrinkle remover creams, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. The company was formerly known as Décor Products International, Inc. and changed its name to ViaDerma, Inc. in May 2014. ViaDerma, Inc. was incorporated in 2007 and is headquartered in Marina Del Rey, California.
IPO date
Jun 10, 2008
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
600
11.07%
541
5.18%
Cost of revenue
196
197
Unusual Expense (Income)
NOPBT
600
540
NOPBT Margin
99.97%
99.96%
Operating Taxes
4
3
Tax Rate
0.00%
0.00%
NOPAT
600
540
Net income
4
-99.31%
591
-159.41%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
323
415
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
313
405
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
(1,265)
(50)
Balance
Cash
10
10
Long term investments
Excess cash
Stockholders' equity
(13,576)
(13,580)
Invested Capital
14,022
12,151
ROIC
4.59%
4.45%
ROCE
134.57%
EV
Common stock shares outstanding
1,686,916
983,556
Price
Market cap
EV
EBITDA
600
541
EV/EBITDA
Interest
76
99
Interest/NOPBT
12.73%
18.31%